志贺菌控制性人类感染模型共识报告:导论与概述
该共识报告介绍志贺菌控制性人类感染模型(CHIM)已在美国3个站点建立,可揭示疾病过程、发病机制与免疫机制,并为多种疫苗提供效力提示。报告描述各站点最佳实践的统一,以最大化CHIM对志贺菌疫苗研发的贡献。
要点
- 志贺菌CHIM已在美国3个站点建立,可用于评估疫苗效力线索。
- CHIM有助于理解志贺菌病的疾病过程、发病机制和免疫机制。
- 各站点最佳实践的统一旨在加速志贺菌疫苗候选物的研发。
核心结论
- 志贺菌CHIM已在美国3个站点建立,并可能对推进志贺菌疫苗候选物研发发挥重要监管作用。
- 该增刊描述各站点最佳实践的统一,以最大化CHIM研究对志贺菌疫苗研发的贡献。
研究设计与样本
- 本文为Clin Infect Dis刊载的志贺菌控制性人类感染模型共识报告,属导论与概述部分。
- 共识报告描述美国3个CHIM站点的最佳实践统一。
主要发现
- CHIM已可用于多种感染原,并有助于理解疾病过程、发病机制和免疫机制。
- CHIM研究通过提供疫苗效力提示,对多种疫苗的研发推进有显著贡献。
临床怎么用
- 感染科医生可关注CHIM作为志贺菌疫苗研发与效力评估的辅助研究平台。
- 临床实践中需了解CHIM研究结果可为疫苗候选物推进提供效力线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, controlled human infection models (CHIMs) have become available for a range of infectious agents and have proved invaluable for understanding the disease process, pathogenesis, and mechanisms of immunity. CHIM studies have also contributed significantly to advancing development of a number of vaccines by providing an indication of vaccine efficacy. The Shigella CHIM has been established in 3 sites in the United States, and it is likely that the CHIM will play an important regulatory role for advancing the range of Shigella vaccine candidates that are currently in development. This supplement describes the harmonization of best practices across sites, with a view to maximizing the contribution that CHIM studies can make to Shigella vaccine development.
引用
- MacLennan CA, Aguilar AO, Steele AD, et al. Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview. Clin Infect Dis. 2019. PMID: 31816066. doi:10.1093/cid/ciz886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。